

ASX Announcement

Race secures sixth US patent for Zantrene®

United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF

19 October 2021 – Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US patent no. 11,147,800) on its cancer drug, Zantrene® (bisantrene dihydrochloride), by the United States Patent and Trademarks Office (USPTO). This patent expires on 25 July 2034.

This is Race’s sixth granted patent on Zantrene in the United States. *“The new US patent provides Race with further protection around uses of Zantrene (and related chemical structures) that improve the efficacy of Zantrene treatments”*, said Race’s CEO Phillip Lynch.

This new patent further expands the therapeutic utility of Zantrene (and related chemical structures), in particular - methods that improve the therapeutic efficacy of Zantrene and reduce side effects.

The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192), 2020 (US 10,548,876) and in 2021 (US 11,135,201), further strengthening Race’s growing IP position for Zantrene.

ENDS

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene.

Learn more at www.raceoncology.com.



Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au